By G HossainPosted on March 11, 2026Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs Orforglipron, Eli Lilly’s oral obesity drug, is under FDA review with a decision expected in April. The pharma has also filed for marketing authorization for the pill in China. Lilly Pumps $3B Into China To Boost Supply of Weight Loss Pill Post navigation Amgen Trims Horizon Subsidiary, f5 Shuts DownDatarails declares traditional FP&A dead, releases FinanceOS platform